Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026)
Pharvaris (PHVS) reported Cash from Investing Activities of -$60992.3 for Q1 2026, up 63.99% on a YoY basis from -$37193.7 in Q1 2025, and down 3306.82% quarter-over-quarter from -$1790.3 in Q4 2025.
Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Pharvaris has reported Cash from Investing Activities for 7 years, with the latest figure at -$60992.3 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 63.99% year-over-year to -$60992.3; the trailing twelve-month figure through Mar 2026 stood at $5.4 billion (up 254.53% YoY), and the FY2025 full-year result was -$185988.4, up 68.06% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$60992.3, down from -$1790.3 in the prior quarter.
- The five-year high for Cash from Investing Activities was $168.8 billion in Q3 2025, with the low at -$163.4 billion in Q2 2025.
- Historically, Cash from Investing Activities has averaged $402.8 million across 5 years, with a median of -$30535.2 in 2023.
- The largest YoY upside for Cash from Investing Activities was 114742419.94% in 2023 against a maximum downside of 236328759.87% in 2023.
- Pharvaris' Cash from Investing Activities stood at -$24117.6 in 2022, then declined by 26.61% to -$30535.2 in 2023, then sank by 463.14% to -$171955.2 in 2024, then soared by 98.96% to -$1790.3 in 2025, then tumbled by 3306.82% to -$60992.3 in 2026.
- The last three Cash from Investing Activities figures came in at -$60992.3 (Q1 2026), -$1790.3 (Q4 2025), and $168.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -60,992.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60,992.34 |
| Mar 31, 2026 | -60,992.34 |
| Dec 31, 2025 | -1,790.30 |
| Dec 31, 2025 | -1,790.30 |
| Sep 30, 2025 | 168.77 Bn |
| Sep 30, 2025 | 168.77 Bn |
| Jun 30, 2025 | -163.42 Bn |
| Jun 30, 2025 | -163.42 Bn |
| Mar 31, 2025 | -169,356.55 |
| Mar 31, 2025 | -169,356.55 |
| Dec 31, 2024 | -171,955.17 |
| Dec 31, 2024 | -171,955.17 |
| Sep 30, 2024 | 77.80 Bn |
| Sep 30, 2024 | 77.80 Bn |
| Jun 30, 2024 | -76.29 Bn |
| Jun 30, 2024 | -76.29 Bn |
| Mar 31, 2024 | -33,360.00 |
| Mar 31, 2024 | -33,360.00 |
| Dec 31, 2023 | -30,535.17 |
| Dec 31, 2023 | -30,535.17 |